Molecular dynamics simulations of GLP-1R binding — computational data

TrialTracker_MD said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Thank you for spelling out the reasoning rather than just the conclusion. Printing the relevant bit and taking it with me.

Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Dr.RenalNash said:

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

I read this differently from Dr.RenalNash, on substance rather than tone. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.

The figures, for anyone assembling their own picture. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. No action needed from anybody.